The FDA has issued a Complete Response Letter to Telix Pharmaceuticals regarding the NDA for TLX101-CDx for the imaging of gliomas.

An intensive blood pressure reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and older with untreated hypertension.

Hyperactivation of certain brain regions in children and adolescents with ARFID suggest a new neurobiological circuit associated with the disorder.